c-Myb associates with PML in nuclear bodies in hematopoietic cells

Experimental Cell Research

Volumn 297, Issue 1, 2004, Pages 118-126

  Dahle, Øyvind ^a   Bakke, Oddmund ^a   Gabrielsen, Odd Stokke ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

c Myb; Nuclear bodies; PML; Transcription

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN C MYB; SUMO 1 PROTEIN;

ANIMAL CELL; ARTICLE; CELL NUCLEUS INCLUSION BODY; GENE ACTIVITY; GENE EXPRESSION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 2942608054     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.03.014     Document Type: Article

References (48)

1. Oh I.H., Reddy E.P. The myb gene family in cell growth, differentiation and apoptosis. Oncogene. 18:1999;3017-3033
2. Mucenski M.L., McLain K., Kier A.B., Swerdlow S.H., Schreiner C.M., Miller T.A., Pietryga D.W., Scott W.J.J., Potter S.S. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell. 65:1991;677-689
3. Taylor D., Badiani P., Weston K. A dominant interfering Myb mutant causes apoptosis in T cells. Genes Dev. 10:1996;2732-2744
4. Pearson R., Weston K. c-Myb regulates the proliferation of immature thymocytes following beta-selection. EMBO J. 19:2000;6112-6120
5. Allen R.D. III, Bender T.P., Siu G. c-Myb is essential for early T cell development. Genes Dev. 13:1999;1073-1078
6. Emambokus N., Vegiopoulos A., Harman B., Jenkinson E., Anderson G., Frampton J. Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb. EMBO J. 22:2003;4478-4488
7. Ness S.A. The Myb oncoprotein: regulating a regulator. Biochim. Biophys. Acta. 1288:1996;F123-F139
8. Lauder A., Castellanos A., Weston K. c-Myb transcription is activated by protein kinase B (PKB) following interleukin 2 stimulation of Tcells and is required for PKB-mediated protection from apoptosis. Mol. Cell. Biol. 21:2001;5797-5805
9. Graf T. Myb: a transcriptional activator linking proliferation and differentiation in hematopoietic cells. Curr. Opin. Genet. Dev. 2:1992;249-255
10. Lipsick J.S., Wang D.M. Transformation by v-Myb. Oncogene. 18:1999;3047-3055
11. Ganter B., Lipsick J.S. Myb and oncogenesis. Adv. Cancer Res. 76:1999;21-60
12. Kowenz-Leutz E., Herr P., Niss K., Leutz A. The homeobox gene GBX2, a target of the myb oncogene, mediates autocrine growth and monocyte differentiation. Cell. 91:1997;185-195
13. Vorbrueggen G., Lovric J., Moelling K. Functional analysis of phosphorylation at serine 532 of human c-Myb by MAP kinase. Biol. Chem. 377:1996;721-730
14. Miglarese M.R., Richardson A.F., Aziz N., Bender T.P. Differential regulation of c-Myb-induced transcription activation by a phosphorylation site in the negative regulatory domain. J. Biol. Chem. 271:1996;22697-22705
15. Aziz N., Miglarese M.R., Hendrickson R.C., Shabanowitz J., Sturgill T.W., Hunt D.F., Bender T.P. Modulation of c-Myb-induced transcription activation by a phosphorylation site near the negative regulatory domain. Proc. Natl. Acad. Sci. U.S.A. 92:1995;6429-6433
16. Aziz N., Wu J., Dubendorff J.W., Lipsick J.S., Sturgill T.W., Bender T.P. c-Myb and v-Myb are differentially phosphorylated by p42mapk in vitro. Oncogene. 8:1993;2259-2265
17. Sano Y., Ishii S. Increased affinity of c-Myb for CREB-binding protein (CBP) after CBP-induced acetylation. J. Biol. Chem. 276:2001;3674-3682
18. Tomita A., Towatari M., Tsuzuki S., Hayakawa F., Kosugi H., Tamai K., Miyazaki T., Kinoshita T., Saito H. c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300. Oncogene. 19:2000;444-451
19. Dahle O., Andersen T.O., Nordgard O., Matre V., Del Sal G., Gabrielsen O.S. Transactivation properties of c-Myb are critically dependent on two SUMO-1 acceptor sites that are conjugated in a PIASy enhanced manner. Eur. J. Biochem. 270:2003;1338-1348
20. Bies J., Markus J., Wolff L. Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. J. Biol. Chem. 277:2002;8999-9009
21. Seeler J.S., Dejean A. SUMO: of branched proteins and nuclear bodies. Oncogene. 20:2001;7243-7249
22. Chang K.S., Fan Y.H., Andreeff M., Liu J., Mu Z.M. The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood. 85:1995;3646-3653
23. Muller S., Matunis M.J., Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17:1998;61-70
24. Salomoni P., Pandolfi P.P. The role of PML in tumor suppression. Cell. 108:2002;165-170
25. Cassinat B., Chomienne C. Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management. Oncogene. 20:2001;7154-7160
26. Jensen K., Shiels C., Freemont P.S. PML protein isoforms and the RBCC/TRIM motif. Oncogene. 20:2001;7223-7233
27. Bloch D.B., Chiche J.D., Orth D., de la Monte S.M., Rosenzweig A., Bloch K.D. Structural and functional heterogeneity of nuclear bodies. Mol. Cell. Biol. 19:1999;4423-4430
28. Yang S., Kuo C., Bisi J.E., Kim M.K. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat. Cell Biol. 4:2002;865-870
29. Engelhardt O.G., Boutell C., Orr A., Ullrich E., Haller O., Everett R.D. The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML. Exp. Cell Res. 283:2003;36-50
30. Everett R.D., Earnshaw W.C., Findlay J., Lomonte P. Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110. EMBO J. 18:1999;1526-1538
31. Negorev D., Ishov A.M., Maul G.G. Evidence for separate ND10-binding and homo-oligomerization domains of Sp100. J. Cell. Sci. 114:2001;59-68
32. Venere M., Mochan T.A., Halazonetis T.D. Chk2 leaves the PML depot. Nat. Cell Biol. 4:2002;E255-E256
33. Miranda G.A., Villalvazo M., Galic Z., Alva J., Abrines R., Yates Y., Evans C.J., Aguilera R.J. Combinatorial regulation of the murine RAG-2 promoter by Sp1 and distinct lymphocyte-specific transcription factors. Mol. Immunol. 38:2002;1151-1159
34. Fogal V., Gostissa M., Sandy P., Zacchi P., Sternsdorf T., Jensen K., Pandolfi P.P., Will H., Schneider C., Del Sal G. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19:2000;6185-6195
35. Matre V., Hovring P.I., Fjeldheim A.K., Helgeland L., Orvain C., Andersson K.B., Gautvik K.M., Gabrielsen O.S. The human neuroendocrine thyrotropin-releasing hormone receptor promoter is activated by the haematopoietic transcription factor c-Myb. Biochem. J. 372:2003;851-859
36. Sleeman J.P. Xenopus A-myb is expressed during early spermatogenesis. Oncogene. 8:1993;1931-1941
37. Zhong S., Salomoni P., Pandolfi P.P. The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2:2000;E85-E90
38. Borden K.L. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol. Cell. Biol. 22:2002;5259-5269
39. Weston K. Reassessing the role of C-MYB in tumorigenesis. Oncogene. 18:1999;3034-3038
40. Ness S.A. Myb binding proteins: regulators and cohorts in transformation. Oncogene. 18:1999;3039-3046
41. Stein G.S., van Wijnen A.J., Stein J.L., Lian J.B., Montecino M., Choi J., Zaidi K., Javed A. Intranuclear trafficking of transcription factors: implications for biological control. J. Cell. Sci. 113(Pt 14):2000;2527-2533
42. Lallemand-Breitenbach V., Zhu J., Puvion F., Koken M., Honore N., Doubeikovsky A., Duprez E., Pandolfi P.P., Puvion E., Freemont P., de The H. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193:2001;1361-1371
43. Ross S., Best J.L., Zon L.I., Gill G. SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization. Mol. Cell. 10:2002;831-842
44. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P., Pelicci P.G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature. 406:2000;207-210
45. Moller A., Sirma H., Hofmann T.G., Rueffer S., Klimczak E., Droge W., Will H., Schmitz M.L. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res. 63:2003;4310-4314
46. Li H., Leo C., Zhu J., Wu X., O'Neil J., Park E.J., Chen J.D. Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol. Cell. Biol. 20:2000;1784-1796
47. Wu W.S., Vallian S., Seto E., Yang W.M., Edmondson D., Roth S., Chang K.S. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol. Cell. Biol. 21:2001;2259-2268
48. Khan M.M., Nomura T., Kim H., Kaul S.C., Wadhwa R., Shinagawa T., Ichikawa-Iwata E., Zhong S., Pandolfi P.P., Ishii S. Role of pml and pml-raralpha in mad-mediated transcriptional repression. Mol. Cell. 7:2001;1233-1243